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The interleukin-2 receptor (IL-2R) is composed of one
affinity-modulating subunit (IL-2R) and two essential
signaling subunits (IL-2R and c). Although most
known signaling events are mediated through tyrosine
residues located within IL-2R, no functions have yet
been ascribed to c tyrosine residues. In this study, we
describe a role for c tyrosines in anti-apoptotic signal
transduction. We have shown previously that a tyrosine-
deficient IL-2R chain paired with wild type c stimu-
lated enhancement of bcl-2 mRNA in IL-2-dependent T
cells, but it was not determined which region of the
IL-2R or which pathway was activated to direct this
signaling response. Here we show that up-regulation of
Bcl-2 by an IL-2R lacking IL-2R tyrosine residues leads
to increased cell survival after cytokine deprivation;
strikingly, this survival signal does not occur in the
absence of c tyrosine residues. These c-dependent sig-
nals are revealed only in the absence of IL-2R ty-
rosines, indicating that the IL-2R engages at least two
distinct signaling pathways to regulate apoptosis and
Bcl-2 expression. Mechanistically, the c-dependent sig-
nal requires activation of Janus kinases 1 and 3 and is
sensitive to wortmannin, implicating phosphatidyli-
nositol 3-kinase. Consistent with involvement of phos-
phatidylinositol 3-kinase, Akt can be activated via tyro-
sine residues on c. Thus, c mediates an anti-apoptotic
signaling pathway through Akt which cooperates with
signals from its partner chain, IL-2R.
Defining the molecular mechanisms by which cytokines and
their receptors trigger signal transduction has been the focus of
intensive research. Indeed, a detailed understanding of cyto-
kine receptor structure and dynamics at the molecular level
has proven useful in several therapeutic modalities to treat
cancer and autoimmune diseases (1, 2). This paper focuses on
structure-function relationships in the interleukin (IL)1-2 re-
ceptor (IL-2R), which is a prototypical member of the type I
cytokine receptor superfamily (3). IL-2 is a crucial regulator of
T cell proliferation, survival, and programmed cell death (apo-
ptosis) (for review, see Ref. 4). The IL-2R is a highly complex
receptor that employs multiple subunits to activate a remark-
able variety of cellular signaling cascades (for review, see Ref.
5). Despite a wealth of information about the IL-2R system
gained in the last decade, it is still not fully understood how the
various subunits within the IL-2R act in a coordinated fashion
to trigger a coherent array of signaling pathways.
Most cytokine receptors are composed of multiple subunits,
existing either as homomers of identical subunits (such as the
erythropoietin (EPO) and tumor necrosis factor receptors) or as
heteromers of distinct proteins (such as the IL-2 and interferon
receptors). In addition, many cytokine receptor complexes
share one or more subunits with other receptors; this is espe-
cially true of the type I family of cytokine receptors. The mem-
bers of this family are characterized by several conserved struc-
tural features, including spaced cysteines and WSXWS motifs
in their extracellular domains, and canonical box 1 and box 2
domains and tyrosine residues in their cytoplasmic tails. There
are several subfamilies of the type I receptors, which are de-
fined by the subunits that they share. For instance, the IL-3, -5,
and granulocyte-macrophage colony-stimulating factor recep-
tors employ an identical receptor subunit termed c, and the
IL-6 family of receptors shares the gp130 subunit (for review,
see Ref. 6). Similarly, the IL-2 family of receptors is defined by
their use of the common  (c) subunit. Originally identified as
the IL-2R chain (7), c is now recognized to be an essential
component of the IL-2, -4, -7, -9, -15, and -21 receptors (8, 9).
Humans with genetic deficiencies in c suffer X-linked severe
combined immunodeficiency syndrome caused by a phenotypic
loss of these cytokines (for review, see Refs. 8 and 10).
Upon interaction with their ligands, type I cytokine receptors
activate numerous downstream signaling molecules, including
Janus kinases (JAK), signal transducers and activators of tran-
scription (STAT), mitogen-activated protein kinases (MAPK),
phosphatidylinositol 3-kinase (PI3K), and/or suppressors of
cytokine signaling. Signaling pathways involving these mole-
cules are initiated by recruiting signaling intermediates to the
receptor complex, usually to phosphorylated tyrosines located
on the receptor’s cytoplasmic tail. In some cases, signaling
molecules bind directly to the receptor, via phosphotyrosine-
binding motifs such as Src homology 2 or phosphotyrosine
binding domains. Alternatively, sometimes one or more adap-
tor molecules are used to bridge the signaling intermediate to
the receptor. Therefore, tyrosines in cytokine receptor tails are
crucial launching points for signaling pathways, and much
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effort has been directed to mapping specific signaling pathways
to individual tyrosine residues within cytokine receptors (e.g.
Refs. 11 and 12).
At the level of the receptor, it is clear that signaling requires
a cooperative interaction between receptor subunits. Indeed,
for nearly all cytokines, dimerization or multimerization of
receptor subunits is essential for signaling (13). In the case of
receptors belonging to the type I family, mutational analyses
have shown that both subunits in the complex must have
functional JAK binding domains, which are located in the con-
served box 1 and box 2 domains (14). Dimerization then per-
mits trans-phosphorylation and subsequent activation of the
associated JAKs (15, 16) followed by phosphorylation of the
receptor tails on distal tyrosine residues.
Apart from JAK activation, are all subunits within a mul-
timeric receptor complex necessary for signal transduction? In
some circumstances, effective signaling is maintained even
when large distal regions of the receptors are deleted by mu-
tagenesis. For example, in the homodimeric erythropoietin re-
ceptor (EPOR), it has been shown that both JAK2 binding sites
within the receptor tail must be present for STAT activation,
but only one distal tail is required to be present (16). Fre-
quently, multiple tyrosines within the cytoplasmic tail of a
single receptor are able to activate identical pathways. For
instance, in the EPOR, four different tyrosine residues are
capable of activating the transcription factor STAT5 (17–19).
Thus, homodimeric receptors apparently contain duplicated
signaling domains, any one of which can activate downstream
pathways such as STAT activation. Although these duplicated
domains may serve to amplify or fine tune signaling responses
(as has been demonstrated for tyrosine-containing motifs in the
T cell receptor (20)), they may serve as redundant or “backup”
mechanisms to ensure that essential pathways are activated.
Duplicated signaling domains also appear to exist in hetero-
meric receptors such as the IL-2R, although the receptor sub-
units contribute differentially to signaling (5, 12, 21–24). The
IL-2R is composed of three subunits, IL-2R (CD25 or Tac),
IL-2R, and c. The IL-2R is an affinity modulator that is
dispensable for signaling, although it is essential in vivo for
detection of physiological levels of IL-2. In contrast, IL-2R and
c are necessary and sufficient for signaling. Both IL-2R and
c are phosphorylated after receptor ligation (25, 26), and both
subunits are highly conserved in mammalian evolution. The
functional roles of tyrosine residues within the IL-2R chain
have been carefully examined, and several important signaling
pathways have been found to be strictly dependent on tyrosines
within this subunit. For example, Tyr-338 recruits the adaptor
molecule Shc and activates the p38-MAPK pathway, leading to
c-fos gene expression (27–29). Moreover, Tyr-338 is the only
tyrosine within the IL-2R complex capable of activating this
pathway. In contrast, three different tyrosine residues (Tyr-
338, Tyr-392, and Tyr-510) all activate STAT5 and prolifera-
tion independently (11, 12). Although multiple IL-2R ty-
rosines can activate these pathways, tyrosines in c cannot do
so. Both the MAPK and STAT5 activation proceed normally
even in the absence of tyrosine residues on c (12, 30). Con-
versely, tyrosines within c cannot compensate for an absence
of tyrosine residues on IL-2R (11, 22, 23). Furthermore, re-
placing c with a heterologous cytokine receptor (the EPOR)
does not have a noticeably deleterious effect on these signals,
as long as IL-2R tyrosines are retained (21). These findings
led to a model in which the only function of the c cytoplasmic
tail is to recruit JAK3 to the receptor complex, whereupon
JAK3 is able to phosphorylate JAK1 and permit subsequent
signaling via phosphorylated tyrosine residues within IL-2R.
Despite the central role of IL-2R tyrosine residues, a num-
ber of signals proceed in the absence of tyrosine residues on the
IL-2R chain. In particular, the gene encoding Bcl-2, an impor-
tant anti-apoptotic effector, is still enhanced by a mutant IL-
2R that cannot be phosphorylated (12). Mutagenesis studies
have indicated that c appears to be crucial for regulating Bcl-2
in vivo even in the absence of its JAK3 binding domain (31).
Moreover, the immune impairment observed in c-deficient
mice can be partially rescued by a bcl-2 transgene (32). There-
fore, given the widespread use of c as a signaling subunit and
the evolutionary conservation of its cytoplasmic tyrosine resi-
dues, we hypothesized that c may engage signaling pathways
in addition to JAK3 activation, possibly through its tyrosine
residues. Accordingly, we show here that tyrosines within the
c subunit mediate a signaling cascade that leads to up-regu-
lation of Bcl-2 and inhibition of apoptosis, thus revealing a
previously unrecognized function for the c subunit in signal
transduction.
EXPERIMENTAL PROCEDURES
Cell Culture, Cell Lines, and Cytokine Stimulations—HT-2 cells
(American Type Culture Collection, Rockville, MD) were maintained in
RPMI 1640, 10% fetal bovine serum (Gemini Bioproducts, Woodland,
CA), 2 mM glutamine, 0.05 mM 2-mercaptoethanol, penicillin/strepto-
mycin, and 1 nM recombinant human IL-2 (generously provided by the
Chiron Corporation, Emeryville, CA). HT-2.EPO and HT-2.EPO cells
were maintained in this medium supplemented with 0.5 mg/ml G418
(Invitrogen). HT-2.EPOYF/, HT-2.EPOABC/, HT-2.EPOABC/
YF, and HT-2.EPOD258A/ cells were maintained in this medium
supplemented with 0.5 mg/ml G418 and 0.4 mg/ml hygromycin B (In-
vitrogen). HT-2.EPO/ and HT-2.EPO/YF cells were maintained in
this medium with recombinant human EPO (5 units/ml, a kind gift from
Amgen, Thousand Oaks, CA) in place of IL-2. HT-2 transfectant cell
lines were prepared as described previously (22). For stimulations, cells
were washed twice in phosphate-buffered saline, stripped with 10 mM
sodium citrate and 140 nM NaCl, and incubated in RPMI 1640 medium
with 1% bovine serum albumin (Sigma) for 4 h. Stimulations were for
indicated times with recombinant human IL-2 (5–10 nM) or EPO (50
units/ml unless otherwise indicated).
Plasmids—All EPO-IL-2R chimeras were expressed in the pCMV4
vector series (33), kindly provided by Dr. M. A. Goldsmith. Construction
of EPO, EPOYF, EPO, and EPOYF has been described elsewhere
(22). EPOABC was made by subcloning a BclI-XbaI fragment from
IL-2RABC (34) into corresponding sites within pCMV4.EPO.
Proliferation Assays—Conventional [3H]thymidine incorporation as-
says were performed as described previously (35). Briefly, 5  103
cells/well were washed twice in phosphate-buffered saline and incu-
bated with EPO or IL-2 for 24 or 48 h in triplicate. Four h prior to
harvesting, 1 Ci/well [3H]thymidine (PerkinElmer Life Sciences) was
added. Cells were harvested on a Skatron microwell harvester (gener-
ously provided by Dr. W. C. Greene, Gladstone Institute of Virology and
Immunology, San Francisco) and analyzed on a Wallac Microbeta coun-
ter (PerkinElmer Life Sciences).
Northern Blotting—Cytoplasmic RNA was prepared from 1–2  107
cells using an RNeasy kit (Qiagen, Valencia, CA) and quantified by
spectrophotometry. Denaturing 1.4% formaldehyde-agarose gels were
prepared with 10 g of RNA/lane, blotted to Zeta probe membranes
(Bio-Rad), and hybridized with 32P-labeled IL-2R, c, or glyceralde-
hyde-3-phosphate dehydrogenase cDNA probes.
Immunoprecipitations and Western Blotting—For immunoprecipita-
tions, 2–3 107 cells were rested for 3–4 h in RPMI 1640 and 1% bovine
serum albumin and stimulated with cytokines. Cells were lysed in
buffer containing 1% Nonidet P-40, 20 mM Tris, pH 8.0, 150 mM NaCl,
50 mM NaF, 100 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, and a 1% protease inhibitor mixture (0.5 mg/ml antipain, 0.5
mg/ml aprotinin, 0.75 mg/ml bestatin, 0.5 mg/ml leupeptin, 0.05 mg/ml
pepstatin, 0.4 mg/ml phosphoramidon, 0.5 mg/ml trypsin inhibitor).
Immunoprecipitations were performed with 1 g of anti-JAK1 antibod-
ies (Santa Cruz Biotechnology, Santa Cruz, CA), 2.5 g of anti-JAK3
antibodies (Upstate Biotechnologies, Saranac NY), or 4 l of anti-Akt1
antibodies (Cell Signaling Technology, Beverly, MA) and protein A- or
protein G-agarose (Roche Molecular Biochemicals). Western blots were
probed with 4G10 anti-phosphotyrosine (Upstate Biotechnologies), an-
ti-phospho-Akt1 (Ser-473), anti-Akt and Bcl-2 (Cell Signaling Technol-
ogy), anti-JAK3, or anti-JAK1 (Santa Cruz Biotechnology).
Flow Cytometry—Apoptosis assays were performed as described pre-
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viously (36). Briefly, cells were incubated with a 1:100 dilution of
GFP-annexin V (a kind gift from Dr. Joel Ernst, University of Califor-
nia, San Francisco (37)) for 20 min on ice, washed in staining buffer
(phosphate-buffered saline, 2% fetal bovine serum, 2.5 mM CaCl), and
resuspended in 1 ml of staining buffer containing 25 ng of propidium
iodide (PI) (Molecular Probes, Eugene, OR). Cells were analyzed on a
FACScan using Cellquest software (BD Biosciences). Intracellular
staining for Bcl-2 was performed by permeabilizing 106 cells/sample
with a Cytoperm/Cytofix kit (Pharmingen) for 30 min on ice. Cells were
washed twice with 1 wash buffer (from kit) and stained for 1–2 h with
a 1:100 dilution of anti-mouse Bcl-2-FITC (clone 3F11) or an isotype-
matched control antibody conjugated to FITC.
RESULTS
Cytoplasmic Tyrosine Residues within IL-2R Are Not
Required for Induction of Bcl-2 or Anti-apoptotic
Signaling
To define regions within IL-2R subunits involved in engaging
anti-apoptotic signal transduction pathways, we used a chi-
meric receptor system previously established in a murine, IL-
2-dependent T cell line, HT-2 (22). To bypass signaling by the
endogenous IL-2R, HT-2 cells were stably transfected with
chimeric receptors composed of the extracellular domain of the
EPOR fused to the transmembrane and cytoplasmic tails of the
IL-2R and c subunits, termed EPO and EPO, respectively
(Fig. 1A). Many prior studies have confirmed that heterodimer-
ization of the EPO and EPO cytoplasmic tails via EPO is
both necessary and sufficient to direct signaling indistinguish-
able from the native IL-2R and that neither EPO nor EPO
co-opts endogenous IL-2R or c subunits for signaling (21, 22,
30). Notably, the EPO/ complex represents both IL-2R- and
IL-15R-dependent signaling because these receptors both con-
tain the IL-2R and c subunits (38–40). Henceforth we shall
refer to our findings as IL-2-dependent, recognizing that these
are presumably the same signals delivered by the IL-15R.
Plasmids encoding the EPO chimeras were stably trans-
fected into HT-2 cells and monoclonal cell lines derived by
limiting dilution. All constructs were found to be highly ex-
pressed, especially compared with endogenous IL-2R and c
levels, as assessed by Northern blotting (Fig. 1B). To show that
the chimeric receptors activated early responses equivalently,
phosphorylation of JAK1 was monitored after treatment with
FIG. 1. A, schematic diagram of the EPO-IL-2R chimeric receptor system. Chimeric receptors composed of the extracellular domain of the murine
EPOR were fused in-frame to the transmembrane and cytoplasmic tails of the human IL-2R and c receptors (originally described in Ref. 22). Box
1 and box 2 regions (which bind to JAKs) are shown. Tyrosine (Y) residues are numbered according to Refs. 7 and 94 and are indicated by circles;
mutations to phenylalanine (F) are indicated by straight lines. Aspartic acid (D)-258 within IL-2R is required for JAK1 activation, and the
IL-2RABC mutant is truncated after amino acid 312 (34). YF indicates a tyrosine-deficient subunit of either IL-2R or c. Although these
chimeric receptors do not incorporate IL-2R, it is well established that this subunit does not contribute to signal transduction by the IL-2R (95).
Note that similar IL-2R chimeric receptor systems have been described by others (96–98). B, expression of EPOR chimeras in HT-2 cells.
Cytoplasmic mRNA was made from the indicated cell lines and separated on a 1.4% denaturing formaldehyde-agarose gel. The RNA was
transferred to a nylon membrane and probed with 32P-labeled cDNAs corresponding to IL-2R, c, and glyceraldehyde-3-phosphate dehydrogenase
(GAPD). Arrows indicate endogenous IL-2R and c bands. The EPOYF construct migrates faster than the EPO construct because of differences
in their 3-untranslated regions. C, activation of JAK1 by chimeric IL-2 receptors. HT-2 cell lines stably transfected with the indicated pairs of
chimeric receptors were rested for 4 h in serum-free medium and incubated without cytokines (U), 50 units/ml EPO (E), or 5 nM IL-2 (2) for 15 min.
Lysates were immunoprecipitated (IP) with anti-JAK1 antibodies, separated by SDS-PAGE on an 8% gel, transferred to nitrocellulose, and probed
with anti-phosphotyrosine (P-Tyr) antibodies (4G10, top panels). Blots were stripped and reprobed with anti-JAK1 antibodies to verify equivalent
loading (bottom panels). Experiments were performed multiple times with similar results and have also been described elsewhere for several of
these cell lines (12, 21, 22).
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EPO or IL-2 (Fig. 1C). Phosphorylation of the JAKs requires
dimerization of the IL-2R with c cytoplasmic tails (15, 22);
therefore, EPO-inducible phosphorylation of JAK1 indicates
that both chimeric receptors are expressed productively on the
cell surface. As shown, JAK1 was phosphorylated equivalently
after IL-2 and EPO treatment in all lines tested except HT-
2.EPOD258A/ cells (where the mutation at Asp-258 disrupts
JAK1 activation (35, 41)) (Fig. 1C). These data indicate that the
EPO chimeras expressed in HT-2 cells are competent to deliver
EPO-inducible signals essentially equivalent to those induced
by the endogenous IL-2R.
IL-2 signaling is known to induce bcl-2 mRNA in hematopoi-
etic cells (12, 42, 43), and both the JAK-STAT and MAPK
pathways have been linked to control of bcl-2 expression (44–
47). However, we found previously that an IL-2R composed of a
tyrosine-deficient IL-2R chain paired with a wild type c
receptor (i.e. the chimera EPOYF/) is able to stimulate up-
regulation of bcl-2 mRNA, thus implicating other signaling
pathways in Bcl-2 expression (12). To show that the EPOYF/
chimera could also up-regulate the Bcl-2 protein, we performed
intracellular staining and Western blotting experiments to
visualize Bcl-2 expression levels (Fig. 2). As expected, in HT-2
cells expressing either the EPO or the EPO chimera alone,
treatment with EPO did not trigger significant increases in
Bcl-2, whereas signaling through the endogenous IL-2R en-
hanced Bcl-2 expression markedly (Fig. 2, A and B). In con-
trast, in HT-2.EPO/ cells, almost equivalent levels of Bcl-2
were induced by both EPO and IL-2 (Fig. 2C). In HT-2.EPO/
YF cells, EPO induced Bcl-2 equivalently to the wild type
IL-2R, indicating that signaling could proceed in the absence of
c tyrosines (Fig. 2D). Strikingly, in HT-2.EPOYF/ cells,
EPO stimulation also caused significant up-regulation of Bcl-2,
albeit somewhat reduced compared with the endogenous IL-2R
(Fig. 2E). A similar pattern of bcl-2 mRNA induction was
observed in HT-2.EPOYF/, HT-2.EPO/YF, and HT-
2.EPO/ cells (data not shown), suggesting that Bcl-2 regula-
tion occurs at the level of mRNA.
To ascertain whether Bcl-2 levels were associated with pro-
ductive anti-apoptotic signals, cytokines were removed from
the growth medium of HT-2.EPO/ or HT-2.EPOYF/ cells,
and cell viability and progression to apoptosis were monitored
by flow cytometry. Cells were treated with IL-2 or EPO and
then stained with PI to test for viability and annexin V coupled
to GFP (GFP-annexin V (37)) to test for apoptosis (Fig. 3). Note
that stimulation of parental HT-2 cells with EPO does not
trigger a detectable anti-apoptotic signal because these cells do
not express endogenous EPO receptors (36). As expected, HT-
2.EPO/ cells exhibited strong protection from apoptosis when
incubated with EPO or IL-2. In addition, only a small percent-
age of the viable cells underwent apoptosis in EPO or IL-2,
whereas most of the viable (PI-negative) cells were apoptotic in
the absence of cytokines (Fig. 3A). In HT-2.EPOYF/ cells,
EPO also induced significant protection from apoptosis (Fig.
3B). Similar to our observations with Bcl-2, the protection
afforded by EPOYF/ was not as vigorous as that by the
FIG. 2. Tyrosines within the IL-2R cytoplasmic tail are not
required for up-regulation of Bcl-2. HT-2.EPO cells (A), HT-
2.EPO cells (B), HT-2.EPO/ cells (C), HT-2.EPO/YF cells (D), and
HT-2.EPOYF/ cells (E) were incubated without cytokines (Unstim,
filled histograms), 50 units/ml EPO (thick solid line), or 10 nM IL-2 (thin
solid line) for 24 h. Cells were permeabilized, stained with anti-Bcl-2-
FITC antibodies, and analyzed by flow cytometry. The thin dotted line
(Control Ig) corresponds to background fluorescence in cells incubated
in IL-2 and stained with isotype-matched control antibodies conjugated
to FITC. Experiments were performed multiple times with comparable
results. Boxed insets, the indicated cell lines were incubated without
cytokines (U) or with EPO (E) or IL-2 (2) for 24 h as described above.
Whole cell lysates were prepared from equivalent cell numbers, sepa-
rated on SDS-PAGE, transferred to nitrocellulose, and probed with
antibodies to murine Bcl-2.
FIG. 3. A tyrosine-deficient IL-2R chain paired with wild type
c protects HT-2 cells from apoptosis caused by IL-2 with-
drawal. HT-2.EPO/ cells (A) and HT-2.EPOYF/ cells (B) were
incubated for 40 h without cytokines (Unstim.) or with 50 units/ml EPO
or 10 nM IL-2, as indicated. Cells were costained with PI and GFP-
annexin V (37) and analyzed by flow cytometry. The top row of histo-
grams shows the viability of the entire population by PI, and the
percentages of viable (PI-negative) cells are indicated. The bottom row
of histograms shows GFP-annexin V staining of PI-negative (boxed)
populations. Data are representative of multiple experiments, and two
independently derived cell lines were tested with similar results.
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native IL-2R or the wild type EPO/ chimeras. Part of the
basis for the decreased survival is likely the reduced Bcl-2 in
these cells (Fig. 2), but additional events may also be required
to maintain long term survival (48). Together, these results
agreed with previous findings that not all signals by the IL-2R
are regulated through IL-2R tyrosine residues (12). These
data also raised the question of whether Bcl-2 induction and
inhibition of apoptosis involve tyrosines on c or could occur
through pathways completely independent of cytoplasmic
tyrosines.
c Tyrosine Residues Are Required for Anti-apoptotic
Signaling in the Absence of IL-2R Tyrosines
The mechanism by which the IL-2R controls Bcl-2 expression
is poorly defined. Most pathways implicated to date involve
signals that depend on tyrosines within IL-2R, such as p38-
MAPK and STAT5 (44–47). To determine whether c tyrosines
can trigger additional pathways that regulate Bcl-2, we created
cell lines expressing a truncated form of the IL-2R chain
(EPOABC) paired with either a wild type c tail (EPO) or a
tyrosine-deficient c tail (EPOYF). The EPOABC mutant
retains the ability to bind and activate JAK1 (Fig. 1C) but does
not contain cytoplasmic tyrosine residues or other distal se-
quences (34). First, we found that the HT-2.EPOABC/ cells
behaved almost identically to the HT-2.EPOYF/ cells with
respect to Bcl-2 induction and survival signaling (Fig. 2 and
Fig. 4, A and B). Thus, there do not appear to be “tyrosine-
independent” signaling motifs in the IL-2R cytoplasmic tail
required for promoting cell survival and Bcl-2 expression.
Strikingly, in the absence of IL-2R tyrosines, c tyrosines
appear to be necessary to mediate up-regulation of Bcl-2. Spe-
cifically, treatment of HT-2.EPOABC/YF cells with EPO
failed to up-regulate Bcl-2 detectably (Fig. 4A). This regulation
occurred at the level of mRNA because treatment with EPO
resulted in increased steady-state levels of bcl-2 message in
HT-2.EPOABC/ cells but not in HT-2.EPOABC/YF
cells (data not shown). These results revealed that although
maximal regulation of Bcl-2 probably requires signals from
IL-2R tyrosines, signals are also relayed from c tyrosine
residues. Moreover, signals initiated directly from JAK1 and/or
JAK3 are not sufficient for Bcl-2 up-regulation (as has been
reported for PI3K activation (49)) because HT-2.EPOABC/
YF cells activate these kinases efficiently.
Consistent with the involvement of c tyrosine residues in
up-regulating Bcl-2, we found that EPO stimulation failed to
provide a survival signal to HT-2.EPOABC/YF cells,
whereas EPO inhibited apoptosis in HT-2.EPOABC/ cells
(Fig. 4B). As with Bcl-2 expression, the anti-apoptotic signal
was reduced compared with that induced through the endoge-
nous IL-2R or EPO/ chimeras. The degree of survival was
very similar to that induced in HT-2.EPOYF/ cells (Fig. 3)
and was consistent among independently derived lines. Be-
cause HT-2.EPO/YF cells maintain the capacity to up-regu-
late Bcl-2 and inhibit apoptosis even in the absence of c
tyrosines (Figs. 2 and 4B), at least two distinct pathways are
initiated by the IL-2R to regulate Bcl-2. Although IL-2R-de-
pendent anti-apoptotic pathways exist which proceed in the
absence of c tyrosines, at least one anti-apoptotic pathway is
mediated through tyrosines within c. These findings highlight
FIG. 4. A, tyrosine residues within c mediate up-regulation of Bcl-2.
HT-2.EPOABC/ cells (top panel) and HT-2.EPOABC/YF cells
(bottom panel) were incubated without cytokines (Unstim) or with 50
units/ml EPO or 10 nM IL-2, and intracellular staining with anti-Bcl-
2-FITC antibodies and Western blots were analyzed as described in Fig.
2. Data are representative of multiple experiments. B, tyrosine residues
within c contribute to anti-apoptotic signaling. The indicated cell lines
were incubated without cytokines (Unstim, white bars) or with 50
units/ml EPO (hatched bars) or 10 nM IL-2 (black bars) and costained
with PI and GFP-annexin V as described in Fig. 3. Percentages of live
cells (% PI-negative) in the total cell population are shown in the top
panel. Percentages of apoptotic cells (% GFP-Annexin V-positive cells
within the PI-negative population) are shown in the bottom panel.
Experiments were performed multiple times, and similar results were
obtained in independently derived cell lines.
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FIG. 5. Anti-apoptotic signaling through c requires both JAK1 and JAK3. A, JAK1 activity is required for up-regulation of Bcl-2.
HT-2.EPOD258A/ cells were incubated without cytokines (Unstim) or with 50 units/ml EPO or 10 nM IL-2 for 24 h, and intracellular staining
and Western blots were performed as described in Fig. 2. Data are representative of multiple experiments. B, JAK1 activity is required for
anti-apoptotic signaling. HT-2.EPOD258A/ and HT-2.EPOYF/ cells were incubated without cytokines (Unstim, white bars) or with 50 units/ml
EPO (hatched bars) or 10 nM IL-2 (black bars). Cells were costained with PI and GFP-annexin V and analyzed by flow cytometry, as described in
Fig. 3. Data are representative of several experiments. C, the JAK3-inhibitor WHI-P154 blocks IL-2-dependent proliferation. HT-2.EPO/ cells
were incubated without cytokines (Unstim., white bars; note that their values are too low to be observed in this graph) or with EPO (50 units/ml)
or 5 nM IL-2 (black bars) in the presence of dimethyl sulfoxide (DMSO) or the indicated concentrations of WHI-P154. [3H]Thymidine incorporation
was monitored after 48 h (similar results were obtained at 24 h; not shown). Experiments were performed in triplicate, and standard deviations
are shown. D, WHI-P154 blocks JAK3 phosphorylation. HT-2 cells were incubated without cytokines (U) or 10 nM IL-2 (2) together with dimethyl
sulfoxide or the indicated concentrations of WHI-P154 for 24 h. Cell lysates were immunoprecipitated (IP) with antibodies to JAK3, separated on
SDS-PAGE, and transferred to nitrocellulose. Membranes were blotted with antibodies to anti-phosphotyrosine (P-Tyr, 4G10, top panels), then
stripped and reprobed with antibodies to JAK3 (bottom panels). E, JAK3 activity is required for Bcl-2 up-regulation through the EPOABC/
chimera. HT-2.EPOABC/ cells were incubated without cytokines (Unstim) or with 50 units/ml EPO or 10 nM IL-2 in the presence of dimethyl
sulfoxide (top panel) or 20 g/ml WHI-P154 (bottom panel). After 24 h, Bcl-2 levels were analyzed by Western blotting and flow cytometry as
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the complex interplay between the IL-2R and c chains in
controlling cell survival.
Mechanisms of Anti-apoptotic Signaling
JAK1 and JAK3 Activation—Many signaling pathways have
been linked to the IL-2R, all of which depend on activation of
JAK1 (for review, see Ref. 50). To confirm that JAK1 was
required for the anti-apoptotic signal mediated by c, HT-
2.EPO cells were stably transfected with a plasmid encoding
EPOD258A, which cannot activate JAK1 (and consequently
JAK3 (15, 34, 41)). EPO stimulation of HT-2.EPOD258A/
cells failed to induce Bcl-2 or protect cells from apoptosis after
cytokine withdrawal (Fig. 5, A and B). In the c-mediated
pathway described here, JAK1 is presumably required for
phosphorylation of JAK3 and subsequently EPO, thus initi-
ating the anti-apoptotic cascade. In this regard, we have dem-
onstrated that EPO is indeed phosphorylated on tyrosine(s)
after stimulation of the receptor (data not shown).
In contrast to JAK1, JAK3 has been suggested to be at least
partly dispensable for regulation of Bcl-2, both in cell lines and
in vivo (31, 51, 52). Therefore, to examine whether JAK3 ac-
tivity is required for survival signaling mediated by c ty-
rosines, we took advantage of a pharmacological inhibitor of
JAK3, WHI-P154 (53). First, we confirmed that WHI-P154
inhibits EPO- and IL-2-induced proliferation in HT-2.EPO/
cells, a signal for which JAK3 is known to be crucial (15, 54).
Proliferation was blocked completely at a concentration of 20
g/ml WHI-P154, consistent with a published report (53) (Fig.
5C). Next, we showed that WHI-P154 at this concentration also
blocked JAK3 phosphorylation (Fig. 5D). Finally, we found that
WHI-P154 blocked Bcl-2 induction and inhibition of apoptosis
through the EPOABC/ receptor (Fig. 5, E and F). The slight
decrease of Bcl-2 in EPO-stimulated cells compared with un-
stimulated cells in the presence of WHI-P154 was not consis-
tently observed. Based on these results, the anti-apoptotic
signaling pathway mediated by c tyrosines appears to be
JAK3-dependent and supports a model in which the JAKs
phosphorylate each other and then the c tail, and c subse-
quently recruits downstream anti-apoptotic signaling
pathways.
Interestingly, although WHI-P154 completely blocked IL-2-
dependent proliferation (Fig. 5C), it only partially blocked anti-
apoptotic signals mediated by the endogenous IL-2R (Fig. 5, E
and F). It is possible that these signals simply show different
sensitivities to this compound. Alternatively, this finding pro-
vides some support for previous (albeit controversial) sugges-
tions that a poorly defined, JAK3-independent signaling path-
way regulates Bcl-2 (see Fig. 7A and Ref. 55) (31, 51, 52).
Distal Signals—Because tyrosines within IL-2R are not
involved in this anti-apoptotic signal, we inferred that neither
the STAT5A/B nor p38-MAPK pathway was responsible. This
hypothesis was confirmed in control experiments showing that
HT-2.EPOABC/ cells did not activate STAT5 phosphoryla-
tion or nuclear import and that inhibitors of various MAPK
pathways had no effect on the anti-apoptotic signal or Bcl-2
up-regulation (data not shown). In addition, we ruled out in-
volvement of the nuclear factor-B pathway because IL-2 sig-
naling does not activate this transcription factor in HT-2 cells.2
A major pathway implicated in anti-apoptotic signaling in-
volves the lipid kinase, PI3K (56, 57; for review, see Ref. 58),
which activates the serine-threonine kinase Akt (also called
protein kinase B). Because several studies have implicated Akt
in anti-apoptotic signaling by IL-2 (59–62), we analyzed Akt
activation in this system. HT-2.EPO/, HT-2.EPOABC/,
or HT-2.EPOABC/YF cells were stimulated with EPO or
IL-2. Whole cell lysates were immunoprecipitated with anti-
bodies to Akt, separated on SDS-PAGE, and Western blots
probed with antibodies specific for the phosphorylated form of
Akt (Ser-473) (Fig. 6A). In all cells there was consistently a
high background phosphorylation of Akt even after the starv-
ing period, a feature common to many T cell lines. As expected,
stimulation of HT-2.EPO/ cells with both EPO and IL-2
induced phosphorylation of Akt over basal levels. EPO stimu-
lation of HT-2.EPOABC/ cells also triggered significant
phosphorylation of Akt, demonstrating that this pathway pro-
ceeds without distal sequences and tyrosines within IL-2R. In
contrast, HT-2.EPOABC/YF cells did not trigger phospho-
rylation of Akt (Fig. 6B), confirming that tyrosines within c
are necessary for this signal. There was a more rapid decline in
phosphorylation of Akt in HT-2.EPOABC/ cells compared
with HT-2.EPO/ cells, suggesting that tyrosines within IL-
2R may be needed to sustain optimal signaling. These data
demonstrate that Akt can be at least partly activated independ-
ently of tyrosines within IL-2R, and its activation correlates
with the anti-apoptotic signaling cascade induced by c.
Because several studies have shown that Akt contributes to
anti-apoptotic signaling in T cells (60, 63), we expected that
blocking this pathway would inhibit the anti-apoptotic path-
way mediated by c tyrosines. Indeed, treatment with the PI3K
inhibitor wortmannin almost completely prevented induction
of Bcl-2 and survival signaling through the EPOABC/ re-
ceptor (Fig. 6, C and D). However, wortmannin exerted only a
mild (though reproducible) inhibitory effect on survival signals
induced through the endogenous IL-2R or wild type EPO
chimeras. Comparable results were obtained using another
PI3K inhibitor, Ly294002 (not shown). These findings suggest
a requirement for the PI3K/Akt family in anti-apoptotic signal-
ing mediated by c. Furthermore, because signaling through
the wild type receptor is only mildly impaired in the presence of
PI3K inhibitors, additional anti-apoptotic pathways independ-
ent of PI3K apparently contribute to survival signaling in the
context of the intact IL-2R (Fig. 7).
DISCUSSION
These data show for the first time that tyrosines within the
common  subunit (c) play a role in mediating signal trans-
duction, as revealed in the IL-2 receptor system. We have
addressed the role of c tyrosines in survival signaling using
chimeric EPOR-IL-2Rs expressed in IL-2-dependent HT-2
cells. The initial impetus for this study was our previous report
that a tyrosine-deficient IL-2R chain paired with a wild type
c subunit (EPOYF/) stimulates significant enhancement of
bcl-2 mRNA, indicating that some intracellular signals can be
transmitted independently of IL-2R tyrosines (12). However,
that study did not define the region within the IL-2R which
mediated this signal, leaving open the possibility that regions
within IL-2R or the JAKs might serve to recruit signaling
effectors that lead to bcl-2 up-regulation. In the present study,
we found that that this signal indeed requires the proximal,
JAK1 binding region of IL-2R and JAK1 activity but does not
require the IL-2R distal tail or cytoplasmic tyrosine residues.
Instead, anti-apoptotic signaling (in the absence of IL-2R2 S. L. Gaffen, unpublished observations.
described in Fig. 2. F, JAK3 activity is required for survival signaling through the EPOABC/ chimera. HT-2.EPOABC/ cells were incubated
without cytokines (Unstim) or with 50 units/ml EPO or 10 nM IL-2 in the presence of dimethyl sulfoxide or 20 g/ml WHI-P154. Viability was
assessed after 30 h by measuring PI uptake by flow cytometry as described in Fig. 3. Data are representative of multiple experiments.
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tyrosines) depends on tyrosines within c. Furthermore, the
serine-threonine kinase Akt is induced by an IL-2R complex
that lacks IL-2R tyrosine residues, and this also requires c
tyrosines. Consistent with a role for the Akt pathway, c-
mediated up-regulation of Bcl-2 and inhibition of apoptosis are
sensitive to PI3K inhibitors. Thus, this work provides the first
evidence that c activates specific signals through its tyrosine
residues.
Functions of c—Surprisingly, very few specific signals to
date have been linked directly to c and none to its tyrosine
residues. The primary recognized role of c is to bind JAK3,
enabling JAK3 to phosphorylate JAK1 and other substrates
recruited to the receptor complex (for review, see Ref. 14). The
biological importance of the c-JAK3 association is underscored
by the finding that c mutations in many X-severe combined
immunodeficiency syndrome patients lie in the JAK3 binding
domain and also that JAK3/ humans and mice exhibit an
autosomal immunodeficiency syndrome very similar to X-se-
vere combined immunodeficiency syndrome (for review, see
Refs. 10 and 64). Although two tyrosine residues are present in
FIG. 6. Anti-apoptotic signaling through c involves the Akt signaling pathway. A, an IL-2R lacking IL-2R tyrosine residues is still
competent to activate Akt. HT-2.EPO/ cells (lanes 1–4) or HT-2.EPOABC/ cells (lanes 5–8) were rested for 4 h in serum-free growth medium
and then incubated without cytokines (0) or with 50 units/ml EPO or 10 nM IL-2 for the indicated time periods. Lysates were immunoprecipitated
with anti-Akt antibodies, separated by SDS-PAGE on an 8% gel, transferred to nitrocellulose, and Western blots probed with antibodies to the
phosphorylated form of Akt (Ser-473, top panel). Blots were stripped and reprobed with anti-Akt antibodies to confirm equivalent loading (center
panel). Note that lanes 1–4 are derived from the same gel. To assess band intensities quantitatively, gels were scanned and analyzed using
Quantity One software (Bio-Rad). The ratio of intensity of the P-Akt band to the Akt band is presented in graphical form in the bottom panel, with
the unstimulated sample for each cell line assigned a value of 1.0. B, tyrosines within c are required for activation of Akt. HT-2.EPOABC/YF
cells were incubated without cytokines (U) or with 50 units/ml EPO (E) or 5 nM IL-2 (2). Lysates were prepared, immunoprecipitated with
antibodies to Akt, and Western blots analyzed as described for A. C, a pharmacological inhibitor of PI3K/Akt blocks up-regulation of Bcl-2 through
c. HT-2.EPOABC/ cells were incubated without cytokines (Unstim) or with 50 units/ml EPO or 10 nM IL-2 in the presence of dimethyl sulfoxide
(DMSO; top panel) or 8 M wortmannin (Wm; bottom panel). After 24 h, Bcl-2 levels were analyzed by Western blotting and flow cytometry as
described in Fig. 2. Data are representative of multiple experiments. D, a pharmacological inhibitor of PI3K blocks survival signaling through c.
HT-2.EPO/ or HT-2.EPOABC/ cells were incubated without cytokines (white bars), 50 units/ml EPO (hatched bars), or 10 nM IL-2 (black bars)
in the presence of dimethyl sulfoxide or 8 M wortmannin. Viability and apoptosis were assessed as in Fig. 3. Similar results were obtained using
another PI3K inhibitor, Ly294002 (not shown). Data are representative of several experiments.
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the JAK3 binding region of c (65), none of the four c tyrosines
is required for JAK3 activation (22, 23, 66, 67). Moreover, the
cytoplasmic domain of c can be functionally replaced with that
of a heterologous receptor (the EPOR), which binds to a differ-
ent Janus kinase (JAK2) with no apparent detriment to signal-
ing (21). Thus, it has long been presumed that tyrosines within
c do not participate in signaling at all, even though c is
phosphorylated after receptor engagement, and its tyrosines
and flanking regions are evolutionarily conserved (25). How-
ever, the present report reveals a role for c tyrosines in anti-
apoptotic signaling which was not identified previously, appar-
ently because of redundant signals transmitted through IL-
2R tyrosines (Fig. 7).
Because c is shared by multiple receptors, there may be a
role for c tyrosine residues in the context of other cytokine
receptors. Similar to the IL-2/15R system, c tyrosines are
dispensable for STAT5 activation by both the IL-7R and IL-9R
(66, 67). Interestingly, however, c tyrosines may play a role in
promoting cell growth by IL-9 because proliferation is reduced
substantially in HT-2 cells expressing an EPO-IL-9R chimera
(EPO9) together with EPOYF compared with EPO9 paired
with EPO (66). It will be interesting to determine whether
close examination of other c-containing receptors identifies an
anti-apoptotic role for c which was not recognized in previous
analyses.
Convergent Survival Signals—The emerging model of signal
transduction is that multiple, overlapping signals converge to
create a coherent and integrated cellular response. Because the
survival signal induced by c is neither as potent nor as pro-
longed as that induced by the wild type IL-2R (Figs. 3 and 4),
additional signals induced through IL-2R tyrosines are appar-
ently required for a complete signal. In support of this concept,
it was recently shown that cytokines control apoptosis by stim-
ulating glucose metabolism, which acts in concert with anti-
apoptotic members of the Bcl-2 family to maintain cellular
survival (48, 68, 69). Although ectopic Bcl-2 expression in vivo
restores some aspects of T cell signaling when c is absent (32),
enforced Bcl-2 expression alone is not sufficient for all aspects
of c-mediated signaling (70, 71). Similarly, activation of the
PI3K pathway by itself is not enough to drive proliferation in a
model T cell line (72).
It is probable that at least one complementary signal derives
from the p38-MAPK pathway. MAPK is activated through the
most membrane-proximal tyrosine within IL-2R (Tyr-338)
(27, 29) and leads to transcription of the c-fos gene (11, 12). In
turn, c-fos cooperates with STAT5, c-myc, and/or bcl-2 to pro-
mote proliferation by IL-2 (43, 72, 73). Similar functional coop-
eration among the STAT5, MAPK, and PI3K pathways is
needed to achieve full oncogenic activity by the BCR/ABL ki-
nase (74). Accordingly, although Bcl-2 is clearly an important
target of cytokine-derived signals, it must act in concert with
other events to regulate appropriate cellular outcomes.
Regulation of Bcl-2 expression by IL-2 is not well understood,
and multiple signaling pathways have been implicated. For
example, p38-MAPK regulates bcl-2 gene expression via the
transcription factor Aiolos, which binds to specific sites in the
bcl-2 promoter (75). STAT5 has also been shown to regulate
Bcl-2 in response to IL-2 (47), IL-7, and IL-15 (46). However,
because IL-2 can also enhance Bcl-2 expression without partic-
ipation of the MAPK or STAT5 pathways (Figs. 2 and 4 and
Refs. 12, 31, 51, 76), the IL-2R appears to activate a variety
downstream signaling pathways that converge on regulation of
Bcl-2 (Fig. 7A).
PI3K Signaling by the IL-2R—It is still not entirely clear
how the IL-2R activates PI3K, which is presumably upstream
of Akt. The classic PI3K isoform is composed of a 110-kDa
catalytic subunit (p110) and an 85-kDa regulatory subunit
(p85), although several other isoforms of PI3K exist. Several
studies have indicated that p85 is recruited through Shc and
Gab2, via Tyr-338 on IL-2R (73, 77, 78). However, another
report implicates IL-2R-Tyr-392 in this process (56). Finally,
a recent study suggests that p85 may bind directly to JAK1
(49). However, if there is constitutive association of p85 with
JAK1 in HT-2 cells, it is not sufficient to mediate a detectable
anti-apoptotic signal in the absence of c tyrosine residues
FIG. 7. A, model of IL-2 receptor signaling pathways that regulate
Bcl-2. Based on our work and that of others, all IL-2-dependent signals
appear to be downstream from JAK1 (51), whereas Bcl-2 may be at least
partially induced by JAK3-independent pathways (Fig. 5 and Refs. 31,
51, and 52). Previous studies have shown that signals initiated through
IL-2R tyrosine residues such as STAT5 and p38-MAPK contribute to
Bcl-2 expression (47, 75). This study demonstrates that in the absence
of other known signals, activation of Akt can be induced via c tyrosine
residues, leading to Bcl-2 enhancement and prolonged cell survival. B,
model of convergent anti-apoptotic signals derived from the IL-2 recep-
tor. Left, wild type IL-2R or wild type EPO/ chimeras deliver a variety
of intracellular signals. Many are initiated at the receptor through
tyrosines within IL-2R, including STAT5 and MAPK. Some reports
also indicate that PI3K is induced through IL-2R tyrosines (for review,
see Ref. 5). Collectively, these signals lead to a long term anti-apoptotic
response as well as a proliferative response. Right, mutant forms of the
IL-2R lacking tyrosine residues (YF or ABC) stimulate an anti-
apoptotic response, trigger activation of Akt, and up-regulate Bcl-2.
Bcl-2 up-regulation and survival are inhibited by wortmannin, and thus
we propose that PI3K/Akt signaling is upstream from enhanced Bcl-2
expression and the resulting anti-apoptotic signal.
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because the EPOABC/YF receptors fail to activate Akt
phosphorylation and anti-apoptotic signaling (Figs. 4 and 6).
Possibly c serves as the first recruitment point for some mem-
ber of PI3K family and then transfers it to JAK1 for subsequent
activation, analogous to a model proposed for JAK3 (41). Other
isoforms of PI3K have been identified which may perform
equivalent functions to p85/p110. Our attempts to coimmuno-
precipitate p85 with c have been unsuccessful,2 suggesting
that the anti-apoptotic signal induced by c may be mediated
by an alternative member of the PI3K family.
Physiological Significance of c-Mediated Signaling—What
is the role of the c-tyrosine-mediated response in vivo? Al-
though no studies have addressed this issue directly, several
findings are consistent with this pathway being biologically
significant. It is clear that IL-2 and IL-15 play important roles
in maintaining immune homeostasis (79–81). IL-2R/ mice
display severe dysregulation in immune homeostasis which
results in fatal autoimmunity (82), and they fail to develop
natural killer cells (83). Reconstitution studies in which dele-
tion mutants of IL-2R were expressed as transgenes in IL-
2R/ mice demonstrated that STAT5 was essential for nat-
ural killer cell development, but immune homeostasis was
maintained even when receptors that cannot activate STAT5 or
MAPK were expressed (84). Consistent with this observation,
long term survival and homeostasis of T cells do not require
STAT5 but instead correlate with Akt stimulation and up-
regulation of Bcl-2 (76). Collectively, these studies imply a role
for both c and PI3K/Akt signaling in maintaining immune
homeostasis.
IL-2R signaling has been proposed to regulate homeostasis
by controlling the persistence of activated peripheral T cells via
Fas and FasL expression, which is also regulated in part by
STAT5 (80, 81, 85). However, peripheral expression of IL-2R
may be dispensable for maintaining T cell homeostasis. When
a wild type IL-2R chain was expressed as a transgene in the
thymus of IL-2R/ mice, they exhibited little or no autoim-
munity even in the absence of detectable peripheral IL-2R
(86), suggesting that IL-2 and/or IL-15 plays a role in develop-
ing thymocytes to maintain immune homeostasis. In support of
this model, IL-2 signaling may be directly involved in negative
selection of major histocompatibility complex class II-restricted
thymocytes (87). Putting these observations together, our find-
ings provide a potential mechanism for how IL-2/15R-depend-
ent signals contribute to immune balance. Namely, anti-apo-
ptotic signaling through c (mediated by Akt and Bcl-2) may
confer prolonged survival on a subset of developing T cells (e.g.
regulatory CD4/CD25 T cells (88)), which ultimately re-
stricts autoreactive peripheral T cells.
Another reason for the IL-2R to activate seemingly redun-
dant pathways may be to allow for a continuum of Bcl-2 ex-
pression levels. It is clear that alterations in Bcl-2 levels exert
potent effects on cellular survival; namely, Bcl-2 overexpres-
sion can be tumorigenic, and its underexpression can cause
apoptosis (for review, see Ref. 89). In addition, several different
signaling cascades influence Bcl-2 expression, such as MAPK
(75), STAT5 (46, 47), c-dependent pathways (Fig. 4), and
JAK3-independent pathways (51, 52) (Fig. 7A). Perhaps each
pathway contributes partially to the levels of Bcl-2, and all are
regulated concurrently to ensure that appropriate expression is
maintained. This model has precedence in antigen receptors
such as the T cell receptor, which encodes multiple, redundant
immunoreceptor tyrosine-based activation motifs (ITAMs) that
recruit similar signaling intermediates and thereby amplify
signaling responses appropriately (20). Thus, the contribution
of c pathways to regulation of Bcl-2 is likely to be biologically
meaningful.
Other Contributors to Anti-apoptotic Signaling—There may
be other anti-apoptotic events triggered by c tyrosines which
we have not yet identified. First, PI3K can lead to activation of
the transcription factor c-myb, which mediates anti-apoptotic
effects including regulation of Bcl-2 (46, 90). Second, the PI3K/
Akt pathway prevents apoptosis through inhibitory phospho-
rylation of the forkhead transcription factor, which controls
expression of pro-apoptotic factors such as Bim (91). Third,
alterations in intracellular pH have been linked to increases in
both pro-apoptotic and anti-apoptotic molecules such as Bcl-2
in the IL-7 system (92). Finally, in some cells IL-2 regulates
secretion of extracellular apoptotic effector molecules, such as
lipocalin (93). It will be interesting to determine whether any of
these events is regulated by c tyrosine residues.
In summary, the IL-2R activates numerous signaling path-
ways, several of which converge to maintain cell survival. We
have shown that at least one of these anti-apoptotic signals is
triggered through tyrosine residues within c and is mediated
by the PI3K/Akt cascade. Importantly, this is the first recogni-
tion of a specific signaling role for c tyrosines, although it
appears to play a subordinate role to the IL-2R chain in IL-2-
and IL-15-dependent signaling. However, given the widespread
use of c among cytokine receptors, this pathway is likely to
have implications for anti-apoptotic signaling in a variety of
contexts.
Acknowledgments—We thank Dr. Mark Goldsmith and Dr. Warner
Greene for plasmids, Dr. Joel Ernst for the kind gift of GFP-annexin V,
and Dr. Warner Greene for generously donating the Skatron cell har-
vester. We thank Dr. Arvind Thakur and Dr. Philip Loverde for use of
the Wallac beta counter. Technical assistance was provided by Stacey
Printup and Grace Wong. EPO was a generous gift from Amgen, Inc.,
and IL-2 was kindly provided by Dr. Kirk Johnson of the Chiron Cor-
poration. We thank Dr. Xin Lin, Dr. James Clements, and Dr. Thomas
Melendy for helpful suggestions.
REFERENCES
1. Waldmann, T. A. (2000) Ann. Oncol. 11, 101–106
2. O’Dell, J. (1999) N. Engl. J. Med. 340, 310–312
3. Bazan, J. F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6934–6938
4. Lenardo, M., Chan, F. K.-M., Hornung, F., McFarland, H., Siegel, R., Wang, J.,
and Zheng, L. (1999) Annu. Rev. Immunol. 17, 221–253
5. Gaffen, S. L. (2001) Cytokine 14, 63–77
6. Ozaki, K., and Leonard, W. J. (2002) J. Biol. Chem. 277, 29355–29358
7. Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N.,
Munakata, H., Nakamura, M., and Sugamura, K. (1992) Science 257,
379–382
8. Leonard, W. J. (1994) Curr. Opin. Immunol. 6, 5631–5635
9. Vosshenrich, C. A. J., and Di Santo, J. P. (2001) Curr. Biol. 11, R175–R177
10. Candotti, F., Notarangelo, L., Visconti, R., and O’Shea, J. (2002) J. Clin.
Invest. 109, 1261–1269
11. Friedmann, M. C., Migone, T.-S., Russell, S. M., and Leonard, W. J. (1996)
Proc. Natl. Acad. Sci. U. S. A. 93, 2077–2082
12. Gaffen, S. L., Lai, S. Y., Ha, M., Liu, X., Hennighausen, L., Greene, W. C., and
Goldsmith, M. A. (1996) J. Biol. Chem. 271, 21381–21390
13. Stroud, R. M., LaPorte, S., and Wells, J. A. (2001) in Cytokine Reference:
Ligands (Oppenheim, J., and Feldmann, M., eds) Vol. 1, pp. 21–34, Aca-
demic Press, San Diego
14. Liu, K. D., Gaffen, S. L., and Goldsmith, M. A. (1998) Cur. Opin. Immunol. 10,
271–278
15. Liu, K. D., Gaffen, S. L., Goldsmith, M. A., and Greene, W. C. (1997) Curr. Biol.
7, 817–826
16. Watowich, S., Liu, K. D., Xie, X., Lai, S. Y., Mikami, A., Longmore, G. D., and
Goldsmith, M. A. (1999) J. Biol. Chem. 274, 5415–5421
17. Damen, J. E., Wakao, H., Miyajima, A., Krosi, J., Humphries, R. K., Cutler,
R. L., and Krystal, G. (1995) EMBO J. 14, 5557–5568
18. Gobert, S., Chretien, S., Gouilleux, F., Muller, O., Pallard, C., Dusanter-Fourt,
I., Groner, B., Lacombe, C., Gisselbrecht, S., and Mayeux, P. (1996) EMBO
J. 15, 2434–2441
19. Klingmuller, U., Bergelson, S., Hsiao, J. G., and Lodish, H. F. (1996) Proc.
Natl. Acad. Sci. U. S. A. 93, 8324–8328
20. Irving, B. A., Chan, A. C., and Weiss, A. (1993) J. Exp. Med. 177, 1093–1103
21. Lai, S. Y., Xu, W., Gaffen, S., Liu, K. D., Greene, W. C., and Goldsmith, M. A.
(1996) Proc. Natl. Acad. Sci. U. S. A. 93, 231–235
22. Goldsmith, M. A., Lai, S. Y., Xu, W., Amaral, M. C., Kuczek, E. S., Parent, L. J.,
Mills, G. B., Tarr, K. L., Longmore, G. D., and Greene, W. C. (1995) J. Biol.
Chem. 270, 21729–21737
23. Nelson, B. H., Lord, J. D., and Greenberg, P. D. (1996) Mol. Cell. Biol. 16,
309–317
24. Nelson, B. H., McIntosh, B. C., Rosencrans, L. L., and Greenberg, P. D. (1997)
Proc. Natl. Acad. Sci. U. S. A. 94, 1878–1883
25. Sugamura, K., Takeshita, T., Asao, H., Kumaki, S., Ohbo, K., Ohtani, K., and
Anti-apoptotic Signals Mediated by c10248
 at SEM
M
ELW
EIS U
N
IV
 O
F M
ED
ICIN
E on M
arch 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Nakamura, M. (1990) Lymphokine Res. 9, 539–543
26. Mills, G. B., May, C., McGill, M., Fung, M., Baker, M., Sutherland, R., and
Greene, W. C. (1990) J. Biol. Chem. 265, 3561–3567
27. Ravichandran, K. S., and Burakoff, S. J. (1994) J. Biol. Chem. 269, 1599–1602
28. Ravichandran, K. S., Igras, V., Schoelson, S. E., Fesik, S. W., and Burakoff,
S. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5275–5280
29. Evans, G., Goldsmith, M. A., Johnston, J. A., Xu, W., Weiler, S. R., Erwin, R.,
Howard, O. M. Z., Abraham, R. T., O’Shea, J. J., Greene, W. C., and Farrar,
W. L. (1995) J. Biol. Chem. 270, 28858–28863
30. Gaffen, S. L., Lai, S. Y., Xu, W., Gouilleux, F., Groner, B., Goldsmith, M. A.,
and Greene, W. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7192–7196
31. Tsujino, S., Di Santo, J. P., Takaoka, A., McKernan, T. L., Noguchi, S., Taya,
C., Yonekawa, H., Saito, T., Taniguchi, T., and Fujii, H. (2000) Proc. Natl.
Acad. Sci. U. S. A. 97, 10514–10519
32. Kondo, M., Akashi, K., Domen, J., Sugamura, K., and Weissman, I. L. (1997)
Immunity 7, 155–162
33. Andersson, S., Davis, D. N., Dahlback, H., Jornvall, H., and Russell, D. W.
(1989) J. Biol. Chem. 264, 8222–8229
34. Goldsmith, M. A., Xu, W., Amaral, M. C., Kuczek, E. S., and Greene, W. C.
(1994) J. Biol. Chem. 269, 14698–14704
35. Goldsmith, M. A., and Greene, W. C. (1994) in The Cytokine Handbook
(Thomson, A., ed) pp. 57–80, Paston Press, Ltd., Norfolk, UK
36. Gaffen, S. L., Lai, S. Y., Longmore, G. D., Liu, K. D., and Goldsmith, M. A.
(1999) Blood 94, 1–14
37. Ernst, J., Yang, L., Rosales, J., and Broaddus, V. (1998) Anal. Biochem. 260,
18–23
38. Giri, J. G., Ahdieh, M., Eisenmann, J., Shanebeck, K., Grabstein, K., Kumaki,
S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. (1994) EMBO J.
13, 2822–2830
39. Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K.,
DuBose, R., Cosman, D., Park, L. S., and Anderson, D. M. (1995) EMBO J.
14, 3654–3663
40. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton,
R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994)
J. Exp. Med. 180, 1395–1403
41. Zhu, M.-H., Berry, J. A., Russell, S. M., and Leonard, W. J. (1998) J. Biol.
Chem. 273, 10719–10725
42. Otani, H., Erdos, M., and Leonard, W. J. (1993) J. Biol. Chem. 268,
22733–22736
43. Miyazaki, T., Liu, Z.-J., Kawahara, A., Minami, Y., Yamada, K., Tsujimoto, Y.,
Barsoumian, E. L., Perlmutter, R. M., and Taniguchi, T. (1995) Cell 81,
223–231
44. Rebollo, A., Dumoutier, L., Renauld, J.-C., Zaballos, A., Ayllon, V., and
Martinez, A. C. (2000) Mol. Cell. Biol. 20, 3407–3416
45. Liu, Y.-Z., Boxer, L. M., and Latchman, D. S. (1999) Nucleic Acids Res. 27,
2086–2090
46. Qin, J. Z., Zhang, C. L., Kamarashev, J., Dummer, R., Burg, G., and Dobbeling,
U. (2001) Blood 98, 2778–2783
47. Lord, J. D., McIntosh, B. C., Greenberg, P. D., and Nelson, B. H. (2000)
J. Immunol. 164, 2533–2541
48. Vander Heiden, M. G., Plas, D. R., Rathmell, J. C., Fox, C. J., Harris, M. H.,
and Thompson, C. B. (2001) Mol. Cell. Biol. 21, 5899–5912
49. Migone, T. S., Rodig, S., Cacalano, N. A., Berg, M., Schreiber, R. D., and
Leonard, W. J. (1998) Mol. Cell. Biol. 18, 6416–6422
50. Taniguchi, T. (1995) Science 178, 251–255
51. Kawahara, A., Minami, Y., Miyazaki, T., Ihle, J. N., and Taniguchi, T. (1995)
Proc. Natl. Acad. Sci. U. S. A. 92, 8724–8728
52. Tsujino, S., Miyazaki, T., Kawahara, A., Maeda, M., Taniguchi, T., and Fujii,
H. (1999) Genes Cells 4, 363–373
53. Sudbeck, E. A., Liu, X. P., Narla, R. K., Mahajan, S., Ghosh, S., Mao, C., and
Uckun, F. M. (1999) Clin. Cancer Res. 5, 1569–1582
54. Russell, S. M., Tayebi, N., Nakajima, H., Reidy, M. C., Roberts, J. L., Aman,
M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., O’Shea,
J. J., and Leonard, W. J. (1995) Science 270, 797–799
55. Suzuki, K., Nakajima, H., Saito, Y., Saito, T., Leonard, W. J., and Iwamoto, I.
(2000) Int. Immunol. 12, 123–132
56. Truitt, K. E., Mills, G. B., Turck, C. W., and Imboden, J. B. (1994) J. Biol.
Chem. 269, 5937–5943
57. Karnitz, L. M., Burns, L. A., Sutor, S. L., Blenis, J., and Abraham, R. T. (1995)
Mol. Cell. Biol. 15, 3049–3057
58. Ward, S. G., and Cantrell, D. A. (2001) Curr. Opin. Immunol. 13, 332–338
59. Reif, K., Burgering, B. M., and Cantrell, D. A. (1997) J. Biol. Chem. 272,
14426–14433
60. Ahmed, N. N., Grimes, H. L., Bellacosa, A., Chan, T. O., and Tsichlis, P. N.
(1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3627–3632
61. Cipres, A., Carrasco, S., and Merida, I. (2001) FEBS Lett. 500, 99–104
62. Kelly, E., Won, A., Refaeli, Y., and Van Parijs, L. (2002) J. Immunol. 168,
597–603
63. Astoul, E., Edmunds, C., Cantrell, D. A., and Ward, S. G. (2001) Trends
Immunol. 22, 490–496
64. Buckley, R. H. (2000) N. Engl. J. Med. 343, 1313–1324
65. Liu, K. D., Lai, S. Y., Goldsmith, M. A., and Greene, W. C. (1995) J. Biol. Chem.
270, 22176–22181
66. Bauer, J., Liu, K. D., Lai, S. Y., You, Y., and Goldsmith, M. A. (1998) J. Biol.
Chem. 273, 9255–9260
67. Lai, S. Y., Molden, J., and Goldsmith, M. A. (1997) J. Clin. Invest. 99, 169–177
68. Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A., and
Thompson, C. B. (2000) Mol. Cell 6, 683–692
69. Rathmell, J. C., Farkash, E. A., Gao, W., and Thompson, C. B. (2001) J. Im-
munol. 167, 6869–6876
70. Rodewald, H. R., Waskow, C., and Haller, C. (2001) J. Exp. Med. 193,
1431–1437
71. Nakajima, H., and Leonard, W. J. (1999) J. Immunol. 162, 782–790
72. Moon, J. J., and Nelson, B. H. (2001) J. Immunol. 167, 2714–2723
73. Lord, J. D., McIntosh, B. C., Greenberg, P. D., and Nelson, B. H. (1998)
J. Immunol. 161, 4627–4633
74. Sonoyama, J., Matsumura, I., Ezoe, S., Satoh, Y., Zhang, X., Kataoka, Y.,
Takai, E., Mizuki, M., Machii, T., Wakao, H., and Kanakura, Y. (2002)
J. Biol. Chem. 277, 8076–8082
75. Romero, F., Martinez, C., Camonis, J., and Rebollo, A. (1999) EMBO J. 18,
3419–3430
76. Van Parijs, L., Refaeli, Y., Lord, J. D., Nelson, B. H., Abbas, A. K., and
Baltimore, D. (1999) Immunity 11, 281–288
77. Gu, H., Maeda, H., Moon, J. J., Lord, J. D., Yoakim, M., Nelson, B. H., and
Neel, B. G. (2000) Mol. Cell. Biol. 20, 7109–7120
78. Cipres, A., Gala, S., Martinez, A. C., Merida, I., and Williamson, P. (1999) Eur.
J. Immunol. 29, 1158–1167
79. Nakajima, H., Liu, X.-W., Wynshaw-Boris, A., Rosenthal, L. A., Imada, K.,
Finbloom, D. S., Hennighausen, L., and Leonard, W. J. (1997) Immunity 7,
691–701
80. Van Parijs, L., and Abbas, A. K. (1998) Science 280, 243–248
81. Refaeli, Y., van Parijs, L., London, C. A., Tschopp, J., and Abbas, A. K. (1998)
Immunity 8, 615–623
82. Suzuki, H., Kundig, T. M., Furlonger, C., Wakeham, A., Timms, E.,
Matsuyama, T., Schmits, R., Simard, J. J. L., Ohashi, P. S., Greisser, H.,
Taniguchi, T., Paige, C. J., and Mak, T. W. (1995) Science 268, 1472–1476
83. Suzuki, H., Duncan, G. S., Takimoto, H., and Mak, T. W. (1997) J. Exp. Med.
185, 499–505
84. Fujii, H., Ogasawara, K., Otsuka, H., Suzuki, M., Yamamura, K., Yokochi, T.,
Miyazaki, T., Suzuki, H., Mak, T. W., Taki, S., and Taniguchi, T. (1998)
EMBO J. 1, 6551–6557
85. Van Parijs, L., Refaeli, Y., Abbas, A. K., and Baltimore, D. (1999) Immunity 11,
763–770
86. Malek, T., Porter, B. O., Codias, E. K., Scibelli, P., and Yu, A. (2000) J. Im-
munol. 164, 2905–2914
87. Bassiri, H., and Carding, S. R. (2001) J. Immunol. 166, 5945–5954
88. Chatenoud, L., Salomon, B., and Bluestone, J. A. (2001) Immunol. Rev. 182,
149–163
89. Adams, J. M., and Cory, S. (1998) Science 281, 1322–1326
90. Lauder, A., Castellanos, A., and Weston, K. (2001) Mol. Cell. Biol. 21,
5797–5805
91. Dijkers, P. F., Birkenkamp, K. U., Lam, E. W., Thomas, N. S., Lammers, J. W.,
Koenderman, L., and Coffer, P. J. (2002) J. Cell Biol. 156, 531–542
92. Khaled, A. R., Reynolds, D. A., Young, H. A., Thompson, C. B., Muegge, K., and
Durum, S. K. (2001) J. Biol. Chem. 276, 6453–6462
93. Devireddy, L. R., Teodoro, J. G., Richard, F. A., and Green, M. R. (2001)
Science 293, 829–834
94. Hatakeyama, M., Tsudo, M., Minamoto, S., Kono, T., Doi, T., Miyata, T.,
Miyasaka, M., and Taniguchi, T. (1989) Science 244, 551–556
95. Hatakeyama, M., Minamoto, S., and Taniguchi, T. (1986) Proc. Natl. Acad. Sci.
U. S. A. 83, 9650–9654
96. Minamoto, S., Treisman, J., Hawkins, W. D., Sugamura, K., and Rosenberg,
S. A. (1995) Blood 86, 2281–2287
97. Nakamura, Y., Russell, S. M., Mess, S. A., Friedmann, M., Erdos, M., Francois,
C., Jacques, Y., Adelstein, S., and Leonard, W. J. (1994) Nature 369,
330–333
98. Nelson, B. H., Lord, J. D., and Greenberg, P. D. (1994) Nature 369, 333–336
Anti-apoptotic Signals Mediated by c 10249
 at SEM
M
ELW
EIS U
N
IV
 O
F M
ED
ICIN
E on M
arch 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Matthew J. Lindemann, Marta Benczik and Sarah L. Gaffen
c) Receptor Subunitγ (γCytoplasmic Tyrosine Residues within the Common 
Anti-apoptotic Signaling by the Interleukin-2 Receptor Reveals a Function for
doi: 10.1074/jbc.M209471200 originally published online January 12, 2003
2003, 278:10239-10249.J. Biol. Chem. 
  
 10.1074/jbc.M209471200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/278/12/10239.full.html#ref-list-1
This article cites 97 references, 60 of which can be accessed free at
 at SEM
M
ELW
EIS U
N
IV
 O
F M
ED
ICIN
E on M
arch 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
